Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Bempedoic acid, especially in combination with ezetimibe, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels, total cholesterol, non-high-density lipoprotein (non-HDL) cholesterol, and high-sensitivity C-reactive protein (hs-CRP) levels in high-risk patients, including those with hypercholesterolemia, established Atherosclerotic Cardiovascular Disease (ASCVD), and statin-intolerant individuals.
• Non-statin regimens demonstrated varying effectiveness, with evolocumab and alirocumab showing the greatest LDL-C reductions, followed by inclisiran, the bempedoic acid/ezetimibe fixed-dose combination, and monotherapies of ezetimibe and bempedoic acid.
• Bempedoic acid independently reduced hsCRP levels, an inflammatory marker, with additional reductions observed when combined with ezetimibe.
• Bempedoic acid use showed no adverse side effects except for potential increases in serum uric acid levels, with monitoring recommended for patients due to this observed rise. There was a trend of higher muscle-related adverse events when bempedoic acid was combined with statins, consistent with those observed with statin monotherapy.
• The combination of bempedoic acid and ezetimibe was associated with a non-significant increase in drug-related and overall adverse events, with a noted potential increased risk of muscle-related adverse events when used with statins.